Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of LEE011 in Hepatic Impairment
NCT02388620Phase 1Completed
- Sponsor
- Novartis
- Start
- Mar 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ribociclib in breast cancer (4 arms), sponsored by Novartis. Primary endpoint: Composite Pharmacokinetic (PK) profile at 14 days. Started Mar 2015; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02388620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388620.